New Drugs Offer Hope for Liver Disease in Type 2 Diabetes
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly common liver condition, particularly affecting individuals with type 2 diabetes (T2D). This review aims to summarize the latest evidence on pharmacologic treatments for MASLD, focusing on drugs already approved for T2D management.
Results
The review found that several glucose-lowering therapies demonstrate meaningful benefits in steatohepatitis (liver inflammation and fat accumulation). Specifically, GLP-1 RAs, dual GIP/GLP-1 RAs, pioglitazone, and SGLT2 inhibitors showed positive effects. > Semaglutide provides the most robust evidence for fibrosis benefit (reduction in liver scarring) in MASLD patients with T2D. Data also suggest potential antifibrotic effects from tirzepatide and dapagliflozin. Furthermore, emerging therapies like resmetirom and semaglutide are the only agents specifically approved for MASLD, highlighting their significant impact. An expanding pipeline, including dual glucagon/GLP-1 and triple GIP/GLP-1/glucagon agonists such as retatrutide, has shown marked reductions in liver fat and signals of MASH benefit (Metabolic dysfunction-associated steatohepatitis improvement).
Why It Matters
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resmetirom as specifically approved for MASLD marks a significant advancement in treatment options. These findings underscore the potential for existing and novel pharmacotherapies to profoundly improve outcomes for millions of patients suffering from both conditions. Continued research and ongoing Phase 3 development of new drug classes, such as pan-PPAR agonists and FGF21 analogues, are crucial for expanding treatment options and improving patient care.